Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2012 | Research

Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma

Authors: Yuan Mao, Da-Wei Zhang, Hong Lin, Lin Xiong, Ying Liu, Qing-Dong Li, Jun Ma, Qing Cao, Ren-Jie Chen, Jin Zhu, Zhen-Qing Feng

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2012

Abstract

Background

Alpha B-crystallin (αB-crystallin) has been suggested to play an important role in the development of solid tumors. However, the association between αB-crystallin expression and clinicopathological characteristics of human laryngeal carcinoma is not well defined. This study aimed to examine the expression of αB-crystallin in human laryngeal squamous cell carcinoma (LSCC) and investigate the relationship between its expression and the prognosis of LSCC.

Methods

Real-time polymerase chain reaction (six LSCC samples, six tumor-adjacent normal samples) and immunohistochemistry by tissue microarrays (109 LSCC samples and 28 tumor-adjacent normal samples) were performed to characterize expression of the αB-crystallin gene in LSCC. Kaplan-Meier survival and Cox regression analyses were carried out to evaluate the prognosis of LSCC.

Results

Real-time polymerase chain reaction and immunohistochemistry analysis showed that the expression of αB-crystallin in LSCC was significantly higher than that in tumor-adjacent normal tissues. Moreover, the expression level of αB-crystallin protein in LSCC was significantly related to alcohol consumption (P = 0.022), tumor differentiation (P = 0.007), pTNM stage (P = 0.041) and 5 years’ survival (P =0.030). COX multi-factor analysis showed that αB-crystallin (P = 0.013), as well as pTNM stage (P =0.027) and lymphatic metastasis (P = 0.015) were independent prognosis factors for LSCC.

Conclusions

The data suggest that αB-crystallin expression is correlated with malignant phenotypes of LSCC and it may serve as a novel prognostic factor for LSCC.

Available only for authorised users

Wu H, Xu H, Zhang S, Wang X, Zhu H, Zhang H, Zhu J, Huang J: Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. Head Neck. 2012, doi:10.1002/hed.23138.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006.CrossRefPubMed

Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, Ang KK, Gay G, Stewart A, Robinson RA: Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006, 116 (9 Pt 2 Suppl 111): 1-13.CrossRefPubMed

Boyle P, Ferlay J: Cancer incidence and mortality in Europe. Ann Oncol. 2005, 16 (3): 481-488. 10.1093/annonc/mdi098.CrossRefPubMed

Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG, Coman WB: Alpha B-crystallin, a new independent marker for poor prognosis in head and neck cancer. Laryngoscope. 2005, 115 (7): 1239-1242. 10.1097/01.MLG.0000164715.86240.55.CrossRefPubMed

Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, Cryns VL: AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest. 2006, 116 (1): 261-270.PubMedCentralCrossRefPubMed

Kamradt MC, Lu M, Werner ME, Kwan T, Chen F, Strohecker A, Oshita S, Wilkinson JC, Yu C, Oliver PG, Duckett CS, Buchsbaum DJ, LoBuglio AF, Jordan VC, Cryns VL: The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem. 2005, 280 (12): 11059-11066. 10.1074/jbc.M413382200.CrossRefPubMed

Adhikari AS, Singh BN, Rao KS, Rao CM: αB-crystallin, a small heat shock protein, modulates NF-κB activity in a phosphorylation-dependent manner and protects muscle myoblasts from TNF-α induced cytotoxicity. Biochim Biophys Acta. 2011, 1813 (8): 1532-1542. 10.1016/j.bbamcr.2011.04.009.CrossRefPubMed

Mao YW, Liu JP, Xiang H, Li DW: Human alphaA- and alphaBcrystallins bind to Bax and Bcl-X(S) to sequester their translocation during staurosporine-induced apoptosis. Cell Death Differ. 2004, 11 (5): 512-526. 10.1038/sj.cdd.4401384.CrossRefPubMed

10.

Chan SK, Lui PC, Tan PH, Yamaguchi R, Moriya T, Yu AM, Shao MM, Hliang T, Wong SI, Tse GM: Increased alpha-B-crystallin expression in mammary metaplastic carcinomas. Histopathology. 2011, 59 (2): 247-255.CrossRefPubMed

11.

Tang Q, Liu YF, Zhu XJ, Li YH, Zhu J, Zhang JP, Feng ZQ, Guan XH: Expression and prognostic significance of the αB-crystallin gene in human hepatocellular carcinoma. Hum Pathol. 2009, 40 (3): 300-305. 10.1016/j.humpath.2008.09.002.CrossRefPubMed

12.

Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, DePinho RA: Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA. 2008, 105 (31): 10703-10708. 10.1073/pnas.0712034105.PubMedCentralCrossRefPubMed

13.

Dimberg A, Rylova S, Dieterich LC, Olsson AK, Schiller P, Wikner C, Bohman S, Botling J, Lukinius A, Wawrousek EF, Claesson-Welsh L: alphaB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. Blood. 2008, 111 (4): 2015-2023. 10.1182/blood-2007-04-087841.CrossRefPubMed

14.

Kase S, He S, Sonoda S, Kitamura M, Spee C, Wawrousek E, Ryan SJ, Kannan R, Hinton DR: alphaB-crystallin regulation of angiogenesis by modulation of VEGF. Blood. 2010, 115 (16): 3398-3406. 10.1182/blood-2009-01-197095.PubMedCentralCrossRefPubMed

15.

Thompson L: World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J. 2006, 85 (2): 74-PubMed

16.

Friedrich M, Villena-Heinsen C, Reitnauer K, Schmidt W, Tilgen W, Reichrath J: Malignancies of the uterine corpus and immunoreactivity score of the DNA “mismatch-repair”enzyme human Mut-S-homologon-2. J Histochem Cytochem. 1999, 47 (1): 113-118. 10.1177/002215549904700112.CrossRefPubMed

17.

Mao Y, Zhang DW, Wen J, Cao Q, Chen RJ, Zhu J, Feng ZQ: A novel LMP1 antibody synergizes with Mitomycin C to inhibit Nasopharyngeal Carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor. Int J Mol Sci. 2012, 13 (2): 2208-2218. 10.3390/ijms13022208.PubMedCentralCrossRefPubMed

18.

Luo XM, Zhou SH, Fan J: Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res. 2010, 38 (6): 1885-1892.CrossRefPubMed

19.

Chen J, Yang B, Zhang S, Ling Y, Ye J, Jia Z, Cao J: Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma. Cancer Gene Ther. 2012, 19 (5): 328-335. 10.1038/cgt.2012.5.CrossRefPubMed

20.

Liang W, Wang XF: In vitro induction of specific anti-tumoral immunity against laryngeal carcinoma by using human interleukin-12 gene-transfected dendritic cells. Chin Med J (Engl). 2011, 124 (9): 1357-1361.

21.

de Souza DL B, Jerez Roig J, Bernal MM: Laryngeal cancer survival in Zaragoza (Spain): a population-based study. Clin Transl Oncol. 2012, 14 (3): 221-224. 10.1007/s12094-012-0787-1.CrossRef

22.

Liu Y, Dong XL, Tian C, Liu HG: Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx. Diagn Pathol. 2012, 7: 34-10.1186/1746-1596-7-34.PubMedCentralCrossRefPubMed

23.

Shi Y, Gong HL, Zhou L, Tian J, Wang Y: CD24: a novel cancer biomarker in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2012, 74 (2): 78-85. 10.1159/000335584.CrossRefPubMed

24.

Liu J, Lei DP, Jin T, Zhao XN, Li G, Pan XL: Altered expression of miR-21 and PTEN in human laryngeal and hypopharyngeal squamous cell carcinomas. Asian Pac J Cancer Prev. 2011, 12 (10): 2653-2657.PubMed

25.

Arrigo AP, Simon S, Gibert B, Kretz-Remy C, Nivon M, Czekalla A, Guillet D, Moulin M, Diaz-Latoud C, Vicart P: Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett. 2007, 581 (19): 3665-3674. 10.1016/j.febslet.2007.04.033.CrossRefPubMed

26.

Gruvberger-Saal SK, Parsons R: Is the small heat shock protein alphaB-crystallin an oncogene?. J Clin Invest. 2006, 116 (1): 30-32.PubMedCentralCrossRefPubMed

27.

Chelouche-Lev D, Kluger HM, Berger AJ, Rimm DL, Price JE: alphaB-crystallin as a marker of lymphnode involvement in breast carcinoma. Cancer. 2004, 100 (12): 2543-2548. 10.1002/cncr.20304.CrossRefPubMed

28.

Jeong WJ, Rho JH, Yoon YG, Yoo SH, Jeong NY, Ryu WY, Ahn HB, Park WC, Rho SH, Yoon HS, Choi YH, Yoo YH: Cytoplasmic and nuclear anti-apoptotic roles of αB-Crystallin in retinal pigment epithelial cells. PLoS One. 2012, 7 (9): e45754-10.1371/journal.pone.0045754.PubMedCentralCrossRefPubMed

29.

Huang Z, Cheng Y, Chiu PM, Cheung FM, Nicholls JM, Kwong DL, Lee AW, Zabarovsky ER, Stanbridge EJ, Lung HL, Lung ML: Tumor suppressor Alpha B-crystallin (CRYAB) associates with the cadherin/catenin adherens junction and impairs NPC progression-associated properties. Oncogene. 2012, 31 (32): 3709-3720. 10.1038/onc.2011.529.CrossRefPubMed

30.

Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H, Lu F, Rustgi AK, Diehl JA: Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell. 2008, 14 (1): 68-78. 10.1016/j.ccr.2008.05.017.PubMedCentralCrossRefPubMed

31.

Stronach EA, Sellar GC, Blenkiron C, Rabiasz GJ, Taylor KJ, Miller EP, Massie CE, Al-Nafussi A, Smyth JF, Porteous DJ, Gabra H: Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. Cancer Res. 2003, 63 (24): 8648-8655.PubMed

32.

Solares CA, Boyle GM, Brown I, Parsons PG, Panizza B: Reduced alphaB-crystallin staining in perineural invasion of head and neck cutaneous squamous cell carcinoma. Otolaryngol Head Neck Surg. 2010, 142 (3 Suppl 1): S15-S19.CrossRefPubMed

33.

Boslooper K, King-Yin Lam A, Gao J, Weinstein S, Johnson N: The clinicopathological roles of alpha-B-crystallin and p53 expression in patients with head and neck squamous cell carcinoma. Pathology. 2008, 40 (5): 500-504. 10.1080/00313020802198010.CrossRefPubMed

Title: Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma
Authors: Yuan Mao
Da-Wei Zhang
Hong Lin
Lin Xiong
Ying Liu
Qing-Dong Li
Jun Ma
Qing Cao
Ren-Jie Chen
Jin Zhu
Zhen-Qing Feng
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2012
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-31-101

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?

BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells

SNPs in DNA repair or oxidative stress genes and late subcutaneous fibrosis in patients following single shot partial breast irradiation

Up-regulation of hypoxia inducible factor-1α by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells

The cost of unresectable stage III or stage IV melanoma in Italy

Whole blood transcriptome correlates with treatment response in nasopharyngeal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer